The average one-year price target for Genmab A (NasdaqGS:GMAB) has been revised to $55.27 / share. This is a decrease of ...

Medicxi will use the €500m kitty to continue supporting drug hunters and entrepreneurs in creating asset-focused ...

Medicxi has closed a €500M fund, expanded its leadership team and outlined its ongoing work in drug development and company ...

Medicxi Announces €500 Million Fund VNew fund will continue Medicxi’s successful asset-centric company creation and investment strategy. LONDON, UK — November 14, 2025 — Medicxi, a leading European ...